Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans.
Elderly subjects (65-76 years) were tested for recall of nonsense syllables prior to and after oral administration of 1-(quinoxalin-6 ylcarbonyl)piperidine (CX516), a centrally active drug that enhances currents mediated by AMPA-type glutamate receptors. A significant and positive drug effect was found for delayed (5 min) recall at 75 min posttreatment; average scores for the highest dose group were more than twofold greater than for the placebo group. The drug had no evident influence on heart rate or self-assessment of several psychological variables.
Lynch
G
G
Cortex Pharmaceuticals, Inc., Irvine, California 92718, USA.
Granger
R
R
Ambros-Ingerson
J
J
Davis
C M
CM
Kessler
M
M
Schehr
R
R
D000368:Aged; D000375:Aging / Q000502:physiology*; D001794:Blood Pressure; D004149:Dioxoles / Q000008:administration & dosage* / Q000097:blood; D006339:Heart Rate; D006801:Humans; D008297:Male; D011939:Mental Recall / Q000187:drug effects*; D018697:Nootropic Agents / Q000008:administration & dosage / Q000097:blood; D010880:Piperidines / Q000008:administration & dosage* / Q000097:blood; D011594:Psychometrics; D018091:Receptors, AMPA / Q000819:agonists* / Q000502:physiology; D013997:Time Factors
C097396:1-(quinoxalin-6-ylcarbonyl)piperidine; D004149:Dioxoles; D018697:Nootropic Agents; D010880:Piperidines; D018091:Receptors, AMPA